Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-08
2006-08-08
Schnizer, Richard (Department: 1635)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C424S133100, C424S139100, C424S141100, C424S142100, C436S547000, C436S548000
Reexamination Certificate
active
07087725
ABSTRACT:
The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.
REFERENCES:
patent: 4921698 (1990-05-01), Shirai et al.
patent: 5200313 (1993-04-01), Carrico
patent: 95/14772 (1995-06-01), None
Altman, Brutlag, Karp, Lathrop, and Searls, Proceedings Second International Conference on Intelligent Systems for Molecular Biology, AAAIPress, Menlo Park, pp. 53-61, 1994.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247:1306-1310 (Mar. 16, 1990).
Miller et al., “Genetic Studies of thelacRepressor. IX. Generation of Altered Proteins by the Suppression of Nonsence Mutations,”J. Mol. Biol.,131:191-222 (1979).
Lennon et al., The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of Genomes and Their Expression,Genomics33:151-152 (Apr. 1996) with Medline Abstract page.
Abreu-Martin et al., 1995, “Divergent Induction of Apoptosis and IL-8 Secretion in HT-29 Cells in Response to TNF-Alpha and Ligation of Fas Antigen”, J. Immunol., 155:4147-4154.
Agematsu, et al., 1995, “CD27/CD70 Interaction Directly Drives B Cell IgG and IgM Synthesis”, Eur. J. Immunol., 25:2825-2829.
Agrawal, 1996, “Antisense Oligonucleotides: towards clinical trials”, Trends Biotechnol., 14:376-387.
Allen et al., 1993,“CD40 Ligand Gene Defects Responsible for X-Linked Hyper-IgM Syndrome”, Science, 259:990-995.
Amakawa et al., 1996, “Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30-Deficient Mice”, Cell, 84:551-562.
Badley et al., 1996, “Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes”, Journal of Virology, 70:199-206.
Banks et al., 1995, “Lymphotoxin-Alpha-Deficient Mice. Effects on Secondary Lymphoid Organ Development and Humoral Immune Responsiveness”, J. Immunol., 155:1685-1693.
Bendele et al., 2000, “Combination Benefit of Treatment with the Cytokine Inhibitors Interleukin-1 Receptor Antagonist and PEGylated Soluble tumor Necrosis Factor Receptor Type I in Animal Models of Rheumatoid Arthritis”, Arthritis Rheum., 43:2648-2659.
Biancone et al., 1995, “Inhibition of the CD40—CD40 Ligand Pathway Prevents Murine Membranous Glomerulonephritis”, Kidney International, 48:458-468.
Bodmer et al., 1997, “TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)”, Immunity, 6:79-88.
Branch, 1998, “A good antisense molecule is hard to find”, TIBS, 23:45-50.
Brojatsch et al., 1996, “CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis”, Cell, 87:845-855.
Browning et al., 1989, “Studies on the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines”, J. Immunology, 143:1859-1867.
Browning et al., 1989, “Studies on the differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines”, J. Immunol., 143:1859-1867.
Browning et al., 1991, “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma”, J. Immunol., 147:1230-1237.
Browning et al., 1993, “Lymphotoxin Beta, A Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface”, Cell, 72:847-856.
Browning et al., 1995, “Characterization of Surface Lymphotoxin Forms”, J. Immunol., 154:33-46.
Browning et al., 1996, “Signaling through the Lymphotoxin β Receptor Induces the Death of Some Adenocarcinoma Tumor Lines”, J. Exp. Med., 183:867-878.
Browning et al., 1996, “Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins Alpha and Beta”, J. of Biological Chemistry, 271:8618-8626.
Browning, et al., 1996, “Signaling through the Lymphotoxin Beta Receptor Induces the Death of Some Adenocarcinoma Tumor Lines”, J. Exp. Med., 183:867-878.
Bucher, P. and A. Bairoch, 1994, “A Generalized Profile Syntax for Biomolecular Sequence Motifs and its Function in Automatic Sequence Interpretation”, Proc. Second International Conference on Intelligent Systems for Molecular Biology, Altman, Brutlag, Karp, Lathrop, Searls (Eds.), 53-61.
Castro et al., 1996, “Fas Modulation of Apoptosis during Negative Selection of Thymocytes”, Immunity, 6:617-627.
Chen, Y.A. and A. B. Shyu, 1995, “AU-Rich Elements: Characterization and Importance in mRNA Degradation”, Trends in Biol. Sci., 20:465-470.
Chicheportiche et al., 1995, “Identification in Mouse Macrophages of a New 4Kb mRNA Present in Hematopoitec Tissues, Which Shares a Short Nucleotide Sequence with Erythropoietin mRNA”, Biochemical and Biophysical Research Communications, 209:1076-1081.
Chicheportiche et al., 1997, “TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family that Weakly Induces Apoptosis”, J. Biol. Chem., 272:32401-32410.
Chinnaiyan et al., 1996, “Signal Transduction by DR3 a Death Domain-Containing Receptor Related to TNFR-1 and CD95”, Science, 274:990-992.
Clark et al., 1992, “TNF in Malaria”, in Tumor Necrosis Factors. The Molecules and Their Emerging Role in Medicine, B. Beutler (Ed.), Raven Press, NY, 303-328.
Cleary et al., 1995, “Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells”, J. Immunol., 155:3329-3337.
Crowe et al., 1994, “A Lymphotoxin-beta-Specific Receptor”, Science, 264:707-710.
Cwirla et al., 1990, “Peptides on Phage: A Vast Library of Peptides for Identifying Ligands”, Proc. Natl. Acad. Sci. USA, 87:6378-6382.
Darnay et al., 1999, “Signal Transduction by Tumor Necrosis Factor and Tumor Necrosis related ligands and their receptors”, Ann. Rheum. Dis., 58 (Suppl. 1):12-113.
De Togni et al., 1994, “Abnormal Development of Peripheral Lymphoid Organs in Mice deficient in Lymphotoxin”, Science, 264:703-707.
DeBenedette et al., 1995, “Role of 4-1BB Ligand in Costimulation of T Lymphocyte Growth and its Upregulation on M12 B Lymphomas by Camp”, J. Exp. Med., 181:985-992.
Degli-Esposti et al., 1997, “Activation of the Lymphotoxin Beta Receptor by Cross-Linking Induces Chemokine Production and Growth Arrest in A375 Melanoma Cells”, J. of Immunol., 158:1756-1762.
Degli-Esposti, 1999, “To die or not to die—the quest of the TRAIL receptors”, Journal of Leukocyte Biology, 65:535-542.
Dermer, 1994, “Another Anniversary for the War on Cancer”, BioTechnology, 12:320.
Devlin et al., 1990, “Random Peptide Libraries: A Source of Specific Protein Binding Molecules”, Science, 249:404-406.
Dias et al., 2001, “The Role of CXC Chemokines in the Regulation of Tumor Angiogenesis”, Cancer Invest., 19:732-738.
Eck et al., 1992, “The Structure of Human Lymphotoxin (Tumor Necrosis factor-Beta) at 1.9-A Resolution”, J. of Biological Chemistry, 267:2119-2122.
Falk et al., 1992, “Expression of the APO-1 Antigen in Burkitt Lymphoma Cell Lines Correlates With a Shift Towards a Lymphoblastoid Phenotype”, Blood, 79:3300-3306.
Fox, David, 1995, “Biological Therapies: A Novel Approach to the Treatment to the Treatment of Autoimmune Disease”, American J. of Medicine, 99:82-88.
Foy et al., 1996, “Immune Regulation by CD40 and Its Ligand GP39”, Annu. Rev. Immunol., 14:591-617.
Funakoshi et al., 1994, “Inhibition of Human B0Cell Lymphoma Growth by CD40 Stimulation”, Blood, 83:2787-2794.
Galle et al.,
Browning Jeffrey
Chicheportiche Yves
Biogen Idec MA Inc.
Fish & Richardson P.C.
Schnizer Richard
The Faculty of Medicine of the University of Geneva
LandOfFree
Antibodies specifically reactive with a tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies specifically reactive with a tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies specifically reactive with a tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3624672